Quantcast

Latest Clinical research Stories

2014-09-03 08:34:03

Features more than 70 in-house counsel, judges, government officials and industry experts in product liability litigation NEW YORK, Sept. 3, 2014 /PRNewswire/ -- American Conference Institute (ACI) is pleased to announce the agenda for its 19(th) Annual Drug and Medical Device Litigation on December 8-10 in New York City. Agenda is now available online. Photo - http://photos.prnewswire.com/prnh/20140903/142346 Featuring 3 new Co-Chairs: Sonia Arnold Counsel-Litigation and Legal Compliance,...

2014-09-03 08:33:57

SEATTLE and VANCOUVER, British Columbia, Sept. 3, 2014 /PRNewswire/ -- CMC Biologics, Inc., a global leader in process development and contract manufacturing, and Zymeworks Inc., a Canadian biotherapeutics company and a world leader in the development of antibody therapeutics, have entered into a Master Services Agreement for process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric) antibody....

2014-09-03 08:33:09

MARLBOROUGH, Mass., Sept. 3, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the Rodman & Renshaw 16(th) Annual Global Investment Conference on Wednesday, September 10, 2014 at 12:05 p.m. EST. Dr....

2014-09-03 08:32:32

- Infinity to Receive $275 Million Upfront Payment and $530 Million in Potential Milestones - CAMBRIDGE, Mass. and NORTH CHICAGO, Ill., Sept. 3, 2014 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE: ABBV) today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer....

2014-09-03 08:32:21

SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate issued by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA conducted an on-site inspection on June 19, 2014 that yielded no critical or major observations. This certification provides clearance to Althea to test commercial...

2014-09-02 23:05:56

Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that in support of its strategic partner, Eli Lilly’s growth, it is to install new automated prefilled syringe clinical packaging lines at its Philadelphia Clinical Supply Center of Excellence. Somerset, N.J. (PRWEB) September 02, 2014 Catalent, the leading global provider of advanced delivery technologies and development...

2014-09-02 20:24:39

CBR International's Scientific Experts Supporting Mapp Biopharmaceutical Pertaining to ZMAPP(TM) BOULDER, Colo., Sept. 2, 2014 /PRNewswire/ -- Dr. Jeanne M. Novak, President and CEO of Boulder, Colorado-based CBR International Corp.(®), a full-service biopharmaceutical product, clinical, medical device and regulatory development and compliance group, has been invited by Dr. Larry Zeitlin, President of Mapp Biopharmaceutical to attend the World Health Organization's Investigational...

2014-09-02 16:25:30

AUSTIN, Texas, Sept. 2, 2014 /PRNewswire/ -- XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix(TM). Xilonix, a True Human(TM) monoclonal antibody therapy, is being evaluated in advanced colorectal cancer patients where disease is further complicated with cachexia. The primary endpoint of the study is overall survival, comparing survival in Xilonix treated patients to a control population provided...

2014-09-02 16:24:25

AUSTIN, Texas, Sept. 2, 2014 /PRNewswire/ -- On July 31, the Food and Drug Administration sent its 60-day notice to Congress that it is moving forward to regulate laboratory-developed tests (LDTs). The clock is now ticking down the minutes until laboratories throughout the U.S. will need to comply with a host of new requirements. Although some medical laboratories may subscribe to the strategy to simply sit back and wait for the FDA to put guidelines in place, it's widely acknowledged that...

2014-09-02 12:28:35

NEW YORK CITY, New York, September 2, 2014 /PRNewswire/ -- Persistence Market Research(http://www.persistencemarketresearch.com) "Global Market Study on Clinical Trial Management System: Asia to Witness Highest Growth by 2019" the global clinical trial management system market was valued at USD 844.0 million in 2013 and is expected to grow at a CAGR of 14% from 2014 to 2019, to reach an estimated value of USD 1,848.5 million in 2019. Browse the full Global Market Study...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related